Tags

Type your tag names separated by a space and hit enter

Apolipoprotein epsilon4 and neuropsychological performance in Alzheimer's disease and vascular dementia.
Neurosci Lett 2010; 483(1):62-6NL

Abstract

The apolipoprotein (APOE) epsilon4 allele is a genetic risk factor for the development of Alzheimer's disease (AD). It has also been associated with vascular dementia (VaD) in some but not all studies. Previous studies have examined the role of APOE in predicting performance on cognitive tests in both demented and non-demented populations. In cognitively intact individuals, statistically significant group differences between APOE epsilon4 carriers and non-carriers have been demonstrated for several cognitive domains. In AD studies of the impact of APOE epsilon4 on cognition have been conflicting while no previous study has assessed cognition and impact of APOE epsilon4 in VaD. In this study we investigated the impact of APOE epsilon4 on performance in neuropsychological tests including information processing speed in patients with mild-moderate AD and VaD. We incorporated both computerized and pen and paper tests to ensure a sensitive method of assessing cognition. 109 patients participated in the study (VaD=41, AD=68). Neurocognitive performance of 44 epsilon4 present AD patients was compared to 24 epsilon4absent patients and performance of 23 epsilon4 present VaD patients was compared to 18 epsilon4 absent patients. There was evidence that APOE epsilon4 conferred a risk of poorer cognitive functioning in both patient groups. In the AD group presence of epsilon4 conferred a negative impact on some measures of speed of information processing and immediate recall while in the VaD group epsilon4 present patients had evidence of poorer accuracy on tasks such as choice reaction time and spatial working memory. In AD and VaD groups epsilon4 present patients showed impairment in selective attention. These findings provide further support of the negative impact of the epsilon4 allele in cognition.

Authors+Show Affiliations

Geriatric Medicine, Centre for Public Health, School of Medicine, Dentistry & Biomedical Sciences, Whitla Medical Building, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom. b.mcguinness@qub.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20678545

Citation

McGuinness, Bernadette, et al. "Apolipoprotein Epsilon4 and Neuropsychological Performance in Alzheimer's Disease and Vascular Dementia." Neuroscience Letters, vol. 483, no. 1, 2010, pp. 62-6.
McGuinness B, Carson R, Barrett SL, et al. Apolipoprotein epsilon4 and neuropsychological performance in Alzheimer's disease and vascular dementia. Neurosci Lett. 2010;483(1):62-6.
McGuinness, B., Carson, R., Barrett, S. L., Craig, D., & Passmore, A. P. (2010). Apolipoprotein epsilon4 and neuropsychological performance in Alzheimer's disease and vascular dementia. Neuroscience Letters, 483(1), pp. 62-6. doi:10.1016/j.neulet.2010.07.063.
McGuinness B, et al. Apolipoprotein Epsilon4 and Neuropsychological Performance in Alzheimer's Disease and Vascular Dementia. Neurosci Lett. 2010 Oct 8;483(1):62-6. PubMed PMID: 20678545.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Apolipoprotein epsilon4 and neuropsychological performance in Alzheimer's disease and vascular dementia. AU - McGuinness,Bernadette, AU - Carson,Robyn, AU - Barrett,Suzanne Lucia, AU - Craig,David, AU - Passmore,Anthony Peter, Y1 - 2010/08/01/ PY - 2010/04/03/received PY - 2010/06/23/revised PY - 2010/07/23/accepted PY - 2010/8/4/entrez PY - 2010/8/4/pubmed PY - 2010/12/14/medline SP - 62 EP - 6 JF - Neuroscience letters JO - Neurosci. Lett. VL - 483 IS - 1 N2 - The apolipoprotein (APOE) epsilon4 allele is a genetic risk factor for the development of Alzheimer's disease (AD). It has also been associated with vascular dementia (VaD) in some but not all studies. Previous studies have examined the role of APOE in predicting performance on cognitive tests in both demented and non-demented populations. In cognitively intact individuals, statistically significant group differences between APOE epsilon4 carriers and non-carriers have been demonstrated for several cognitive domains. In AD studies of the impact of APOE epsilon4 on cognition have been conflicting while no previous study has assessed cognition and impact of APOE epsilon4 in VaD. In this study we investigated the impact of APOE epsilon4 on performance in neuropsychological tests including information processing speed in patients with mild-moderate AD and VaD. We incorporated both computerized and pen and paper tests to ensure a sensitive method of assessing cognition. 109 patients participated in the study (VaD=41, AD=68). Neurocognitive performance of 44 epsilon4 present AD patients was compared to 24 epsilon4absent patients and performance of 23 epsilon4 present VaD patients was compared to 18 epsilon4 absent patients. There was evidence that APOE epsilon4 conferred a risk of poorer cognitive functioning in both patient groups. In the AD group presence of epsilon4 conferred a negative impact on some measures of speed of information processing and immediate recall while in the VaD group epsilon4 present patients had evidence of poorer accuracy on tasks such as choice reaction time and spatial working memory. In AD and VaD groups epsilon4 present patients showed impairment in selective attention. These findings provide further support of the negative impact of the epsilon4 allele in cognition. SN - 1872-7972 UR - https://www.unboundmedicine.com/medline/citation/20678545/Apolipoprotein_epsilon4_and_neuropsychological_performance_in_Alzheimer's_disease_and_vascular_dementia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0304-3940(10)00986-9 DB - PRIME DP - Unbound Medicine ER -